Richard A. Decreau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Richard A. Decreau has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- James P. Collman
Department of Chemistry, Stanford University, Stanford, California 94305, USA
19 shared publications - Yann Bernhard
Université de Lorraine, CNRS, L2CM UMR 7053, F-54506 Vandoeuvre-lès-Nancy, France
10 shared publications Ying Yang
Department of Chemistry, Stanford University, Stanford, CA 94305
10 shared publications- Abhishek Dey
Indian Association for the Cultivation of Science 2A Raja SC Mullick Road
9 shared publications Vivian Lioret
Université Bourgogne Europe, ICMUB UMR CNRS 6302, Dijon 21000, France
9 shared publicationsJames P. Collman
Department of Chemistry, Stanford University, Stanford, California 94305-5080
5 shared publications
Latest Publications
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
Picket fence phthalocyanine bearing a proximal tail as a heme protein mimic
A myoglobin active site model was synthesized from an iron phthalocyanine platform upon covalent attachment of a coordinating proximal tail and distal picket fence.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
Picket fence phthalocyanine bearing a proximal tail as a heme protein mimic
A myoglobin active site model was synthesized from an iron phthalocyanine platform upon covalent attachment of a coordinating proximal tail and distal picket fence.
- 24 January 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (9) , 5429-5437
Liposome: a tool to raise the Cherenkov radiation yield and to restore fluorophore properties in aqueous media
Liposomes used for the study were prepared and carefully characterized multiple times until all batches indicated the same characterization data (DOPC/cholesterol derivative (1 : 1.15 mol%), 14 mg(DOPC) mL−1, dDLS = 130 nm, 2 × 1011 liposome per nm3 of prepared batch, polydispersity index PDI = 0.1). The study shows that such a liposome suspension raises the yield in Cherenkov Radiation (CR) by 1.6-fold when in presence of [68Ga]-GaCl3, an efficient CR emitter (beta particle energy Eβ + = 1800 KeV). Also, liposomes were found to prevent aggregation of a water-soluble phthalocyanine-pyranine PcPy4 dyad upon encapsulation, leading to its spectacular fluorescence restoration. Altogether, upon efficient 68Ga-radiolabelling of NODAGA-chelate immobilized at the liposome surface (99% radiolabelling yield, radio-TLC showed) encapsulating PcPy4 dyad (Caverage = 97 μM, Clumen = 300 μM), subsequent Cherenkov Radiation Energy Transfer (CRET) at the dyad antenna occurred. Internal energy transfers and fluorescence emission from the emitter dyad led to a 2.6-fold raise in radiance measured in the near-infrared (NIR) window (i.e. ca. 400 nm pseudo-Stokes shift). A similar raise in radiance was measured in the green window when encapsulation was achieved with eosin at the same rate. Liposome were found to be stable in PBS over 7 days regardless of the encapsulated fluorophore (no raise in dDLS diameter, no release of encapsulated dyes measured after Sephadex and FPLC repurification sequence), with some decay over 22 hours in a PBS/fetal calf serum mixture (1 : 1 vol.).
- 24 January 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (9) , 5429-5437
Liposome: a tool to raise the Cherenkov radiation yield and to restore fluorophore properties in aqueous media
Liposomes used for the study were prepared and carefully characterized multiple times until all batches indicated the same characterization data (DOPC/cholesterol derivative (1 : 1.15 mol%), 14 mg(DOPC) mL−1, dDLS = 130 nm, 2 × 1011 liposome per nm3 of prepared batch, polydispersity index PDI = 0.1). The study shows that such a liposome suspension raises the yield in Cherenkov Radiation (CR) by 1.6-fold when in presence of [68Ga]-GaCl3, an efficient CR emitter (beta particle energy Eβ + = 1800 KeV). Also, liposomes were found to prevent aggregation of a water-soluble phthalocyanine-pyranine PcPy4 dyad upon encapsulation, leading to its spectacular fluorescence restoration. Altogether, upon efficient 68Ga-radiolabelling of NODAGA-chelate immobilized at the liposome surface (99% radiolabelling yield, radio-TLC showed) encapsulating PcPy4 dyad (Caverage = 97 μM, Clumen = 300 μM), subsequent Cherenkov Radiation Energy Transfer (CRET) at the dyad antenna occurred. Internal energy transfers and fluorescence emission from the emitter dyad led to a 2.6-fold raise in radiance measured in the near-infrared (NIR) window (i.e. ca. 400 nm pseudo-Stokes shift). A similar raise in radiance was measured in the green window when encapsulation was achieved with eosin at the same rate. Liposome were found to be stable in PBS over 7 days regardless of the encapsulated fluorophore (no raise in dDLS diameter, no release of encapsulated dyes measured after Sephadex and FPLC repurification sequence), with some decay over 22 hours in a PBS/fetal calf serum mixture (1 : 1 vol.).
- 24 December 2024
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Chimie
- Vol. 27 (S1) , 91-103
Cherenkov radiation energy transfer from [18F]-fluorodeoxyglucose to subphthalocyanine fluorophores
Cherenkov radiation (CR) is an optical light that is emitted during the decay of beta-particle-emitting radionuclides, such as 18 F, which is present in [ 18 F]-fluorodeoxyglucose, a well-known tracer used in positron emission tomography. The CR emission occurs from relaxation of molecules of the dielectric medium surrounding the emitted beta-particle. The Cherenkov radiation energy transfer (CRET) to a CR acceptor, such as subphthalocyanine, was analyzed. Subphthalocyanine is a unique concave-shaped 14 π -electron fluorophore with optical properties. The relevance of such a CR emitter/acceptor couple to performing CRET is discussed.
- 24 December 2024
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Chimie
- Vol. 27 (S1) , 91-103
Cherenkov radiation energy transfer from [18F]-fluorodeoxyglucose to subphthalocyanine fluorophores
Cherenkov radiation (CR) is an optical light that is emitted during the decay of beta-particle-emitting radionuclides, such as 18 F, which is present in [ 18 F]-fluorodeoxyglucose, a well-known tracer used in positron emission tomography. The CR emission occurs from relaxation of molecules of the dielectric medium surrounding the emitted beta-particle. The Cherenkov radiation energy transfer (CRET) to a CR acceptor, such as subphthalocyanine, was analyzed. Subphthalocyanine is a unique concave-shaped 14 π -electron fluorophore with optical properties. The relevance of such a CR emitter/acceptor couple to performing CRET is discussed.
- 30 September 2023
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 44, 103816
Cherenkov Radiation induced photodynamic therapy - repurposing older photosensitizers, and radionuclides
- 30 September 2023
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 44, 103816
Cherenkov Radiation induced photodynamic therapy - repurposing older photosensitizers, and radionuclides
- Open Access
- 5 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2388
Superparamagnetic Iron Oxide Nanoparticles for Immunotherapy of Cancers through Macrophages and Magnetic Hyperthermia
Cancer immunotherapy has tremendous promise, but it has yet to be clinically applied in a wider variety of tumor situations. Many therapeutic combinations are envisaged to improve their effectiveness. In this way, strategies capable of inducing immunogenic cell death (e.g., doxorubicin, radiotherapy, hyperthermia) and the reprogramming of the immunosuppressive tumor microenvironment (TME) (e.g., M2-to-M1-like macrophages repolarization of tumor-associated macrophages (TAMs)) are particularly appealing to enhance the efficacy of approved immunotherapies (e.g., immune checkpoint inhibitors, ICIs). Due to their modular construction and versatility, iron oxide-based nanomedicines such as superparamagnetic iron oxide nanoparticles (SPIONs) can combine these different approaches in a single agent. SPIONs have already shown their safety and biocompatibility and possess both drug-delivery (e.g., chemotherapy, ICIs) and magnetic capabilities (e.g., magnetic hyperthermia (MHT), magnetic resonance imaging). In this review, we will discuss the multiple applications of SPIONs in cancer immunotherapy, focusing on their theranostic properties to target TAMs and to generate MHT. The first section of this review will briefly describe immune targets for NPs. The following sections will deal with the overall properties of SPIONs (including MHT). The last section is dedicated to the SPION-induced immune response through its effects on TAMs and MHT.
- 5 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2388
Open AccessSuperparamagnetic Iron Oxide Nanoparticles for Immunotherapy of Cancers through Macrophages and Magnetic Hyperthermia
Cancer immunotherapy has tremendous promise, but it has yet to be clinically applied in a wider variety of tumor situations. Many therapeutic combinations are envisaged to improve their effectiveness. In this way, strategies capable of inducing immunogenic cell death (e.g., doxorubicin, radiotherapy, hyperthermia) and the reprogramming of the immunosuppressive tumor microenvironment (TME) (e.g., M2-to-M1-like macrophages repolarization of tumor-associated macrophages (TAMs)) are particularly appealing to enhance the efficacy of approved immunotherapies (e.g., immune checkpoint inhibitors, ICIs). Due to their modular construction and versatility, iron oxide-based nanomedicines such as superparamagnetic iron oxide nanoparticles (SPIONs) can combine these different approaches in a single agent. SPIONs have already shown their safety and biocompatibility and possess both drug-delivery (e.g., chemotherapy, ICIs) and magnetic capabilities (e.g., magnetic hyperthermia (MHT), magnetic resonance imaging). In this review, we will discuss the multiple applications of SPIONs in cancer immunotherapy, focusing on their theranostic properties to target TAMs and to generate MHT. The first section of this review will briefly describe immune targets for NPs. The following sections will deal with the overall properties of SPIONs (including MHT). The last section is dedicated to the SPION-induced immune response through its effects on TAMs and MHT.
- 6 October 2022
- Published by Springer Nature in Photochemical & Photobiological Sciences
- Vol. 22 (2) , 303-309
Water soluble octa-imidazolium zinc phthalocyanine for nucleus/nucleolus cell fluorescence microscopy and photodynamic therapy
A poly-cationic theranostic macrocycle was developed to perform confocal microscopy imaging and photodynamic therapy studies on a model of melanoma cancer, one of the most aggressive cancer. Hence, an octa-imidazolium zinc phthalocyanine was conveniently synthesized in large amount in three steps in a 44% overall yield: upon double nucleophilic aromatic substitution, cyclo-tetramerization and quaternization reactions. Such an octa-cationic molecule was readily soluble in physiological media, reaching concentrations beyond 1 mM. It showed fluorescence properties in aqueous medium (ΦF = 0.31) with no noticeable aggregation, spectroscopy studies showed. In vitro confocal fluorescence microscopy studies carried out on murine melanoma model (B16F10 cells) showed that the fluorophore was mainly located in the cell nucleolus, an organelle of interest for the treatment of cancer. The anticancer photodynamic potential of the octa-cationic photosensitizer could be measured (IC50 = 5.4 µM) using the MTS viability assay. Both fluorescence microscopy studies and photodynamic studies demonstrate the octa-cationic molecule is theranostic and could be further developed for future photodynamic diagnosis (PDD) and photodynamic inactivation of micro-organisms (PDI). Graphical abstract
- 6 October 2022
- Published by Springer Nature in Photochemical & Photobiological Sciences
- Vol. 22 (2) , 303-309
Water soluble octa-imidazolium zinc phthalocyanine for nucleus/nucleolus cell fluorescence microscopy and photodynamic therapy
A poly-cationic theranostic macrocycle was developed to perform confocal microscopy imaging and photodynamic therapy studies on a model of melanoma cancer, one of the most aggressive cancer. Hence, an octa-imidazolium zinc phthalocyanine was conveniently synthesized in large amount in three steps in a 44% overall yield: upon double nucleophilic aromatic substitution, cyclo-tetramerization and quaternization reactions. Such an octa-cationic molecule was readily soluble in physiological media, reaching concentrations beyond 1 mM. It showed fluorescence properties in aqueous medium (ΦF = 0.31) with no noticeable aggregation, spectroscopy studies showed. In vitro confocal fluorescence microscopy studies carried out on murine melanoma model (B16F10 cells) showed that the fluorophore was mainly located in the cell nucleolus, an organelle of interest for the treatment of cancer. The anticancer photodynamic potential of the octa-cationic photosensitizer could be measured (IC50 = 5.4 µM) using the MTS viability assay. Both fluorescence microscopy studies and photodynamic studies demonstrate the octa-cationic molecule is theranostic and could be further developed for future photodynamic diagnosis (PDD) and photodynamic inactivation of micro-organisms (PDI). Graphical abstract
- 1 December 2020
- Published by Elsevier in Dyes and Pigments
- Vol. 183
Pyrene/coumarine-subphthalocyanine conjugates as light harvesting systems with intramolecular energy transfer
- 1 December 2020
- Published by Elsevier in Dyes and Pigments
- Vol. 183
Pyrene/coumarine-subphthalocyanine conjugates as light harvesting systems with intramolecular energy transfer
- 24 July 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (17) , 9446-9456
Dual Cherenkov Radiation-Induced Near-Infrared Luminescence Imaging and Photodynamic Therapy toward Tumor Resection
Cherenkov Radiation (CR), the blue light seen in nuclear reactors is emitted by some radiopharmaceuticals. This study showed that 1) a portion of CR could be transferred in the region of the optical spectrum where biological tissues are most transparent: as a result, upon radiance amplification in the NIR window, the detection of light could occur twice deeper in tissues than during classical Cherenkov Luminescence Imaging (CLI). 2) Cherenkov-Photodynamic Therapy (CR-PDT) on cells could be achieved under conditions mimicking unlimited depth using CR embarked light source, which is unlike standard Photodynamic Therapy (PDT) where light penetration depth is limited in biological tissues. Both results are of utmost importance for simultaneous applications in tumor resection and post-resection treatment of remaining un-resected margins, thanks to a molecular construct designed to raise its light collection efficiency (i.e. CR Energy Transfer (CRET)) by conjugation with multiple CR-absorbing (water-soluble) antenna followed by intramolecular-FRET/TBET energy transfers.
- 24 July 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (17) , 9446-9456
Dual Cherenkov Radiation-Induced Near-Infrared Luminescence Imaging and Photodynamic Therapy toward Tumor Resection
Cherenkov Radiation (CR), the blue light seen in nuclear reactors is emitted by some radiopharmaceuticals. This study showed that 1) a portion of CR could be transferred in the region of the optical spectrum where biological tissues are most transparent: as a result, upon radiance amplification in the NIR window, the detection of light could occur twice deeper in tissues than during classical Cherenkov Luminescence Imaging (CLI). 2) Cherenkov-Photodynamic Therapy (CR-PDT) on cells could be achieved under conditions mimicking unlimited depth using CR embarked light source, which is unlike standard Photodynamic Therapy (PDT) where light penetration depth is limited in biological tissues. Both results are of utmost importance for simultaneous applications in tumor resection and post-resection treatment of remaining un-resected margins, thanks to a molecular construct designed to raise its light collection efficiency (i.e. CR Energy Transfer (CRET)) by conjugation with multiple CR-absorbing (water-soluble) antenna followed by intramolecular-FRET/TBET energy transfers.
- 4 February 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (8) , 2854-2859
Resonant inelastic X-ray scattering determination of the electronic structure of oxyhemoglobin and its model complex
Hemoglobin and myoglobin are oxygen-binding proteins with S = 0 heme {FeO2}8 active sites. The electronic structure of these sites has been the subject of much debate. This study utilizes Fe K-edge X-ray absorption spectroscopy (XAS) and 1s2p resonant inelastic X-ray scattering (RIXS) to study oxyhemoglobin and a related heme {FeO2}8 model compound, [(pfp)Fe(1-MeIm)(O2)] (pfp = meso-tetra(α,α,α,α-o-pivalamido-phenyl)porphyrin, or TpivPP, 1-MeIm = 1-methylimidazole) (pfpO2), which was previously analyzed using L-edge XAS. The K-edge XAS and RIXS data of pfpO2 and oxyhemoglobin are compared with the data for low-spin FeII and FeIII [Fe(tpp)(Im)2]0/+ (tpp = tetra-phenyl porphyrin) compounds, which serve as heme references. The X-ray data show that pfpO2 is similar to FeII, while oxyhemoglobin is qualitatively similar to FeIII, but with significant quantitative differences. Density-functional theory (DFT) calculations show that the difference between pfpO2 and oxyhemoglobin is due to a distal histidine H bond to O2 and the less hydrophobic environment in the protein, which lead to more backbonding into the O2. A valence bond configuration interaction multiplet model is used to analyze the RIXS data and show that pfpO2 is dominantly FeII with 6–8% FeIII character, while oxyhemoglobin has a very mixed wave function that has 50–77% FeIII character and a partially polarized Fe–O2 π-bond. Significance The electronic structure of the heme oxy-iron center in oxyhemoglobin and oxymyoglobin has been the subject of debate for decades. Various experimental and computational methods have been used to study this system, leading to conflicting conclusions. This study uses X-ray spectroscopy to directly probe the iron center in the highly delocalized oxyhemoglobin and its model compound to define the electronic structure and understand the differences between the protein and the model. This study settles a longstanding debate in bioinorganic chemistry and provides insight into heme iron–oxygen binding, the key first step in many biocatalytic processes.
- 4 February 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (8) , 2854-2859
Resonant inelastic X-ray scattering determination of the electronic structure of oxyhemoglobin and its model complex
Hemoglobin and myoglobin are oxygen-binding proteins with S = 0 heme {FeO2}8 active sites. The electronic structure of these sites has been the subject of much debate. This study utilizes Fe K-edge X-ray absorption spectroscopy (XAS) and 1s2p resonant inelastic X-ray scattering (RIXS) to study oxyhemoglobin and a related heme {FeO2}8 model compound, [(pfp)Fe(1-MeIm)(O2)] (pfp = meso-tetra(α,α,α,α-o-pivalamido-phenyl)porphyrin, or TpivPP, 1-MeIm = 1-methylimidazole) (pfpO2), which was previously analyzed using L-edge XAS. The K-edge XAS and RIXS data of pfpO2 and oxyhemoglobin are compared with the data for low-spin FeII and FeIII [Fe(tpp)(Im)2]0/+ (tpp = tetra-phenyl porphyrin) compounds, which serve as heme references. The X-ray data show that pfpO2 is similar to FeII, while oxyhemoglobin is qualitatively similar to FeIII, but with significant quantitative differences. Density-functional theory (DFT) calculations show that the difference between pfpO2 and oxyhemoglobin is due to a distal histidine H bond to O2 and the less hydrophobic environment in the protein, which lead to more backbonding into the O2. A valence bond configuration interaction multiplet model is used to analyze the RIXS data and show that pfpO2 is dominantly FeII with 6–8% FeIII character, while oxyhemoglobin has a very mixed wave function that has 50–77% FeIII character and a partially polarized Fe–O2 π-bond. Significance The electronic structure of the heme oxy-iron center in oxyhemoglobin and oxymyoglobin has been the subject of debate for decades. Various experimental and computational methods have been used to study this system, leading to conflicting conclusions. This study uses X-ray spectroscopy to directly probe the iron center in the highly delocalized oxyhemoglobin and its model compound to define the electronic structure and understand the differences between the protein and the model. This study settles a longstanding debate in bioinorganic chemistry and provides insight into heme iron–oxygen binding, the key first step in many biocatalytic processes.
- Open Access
- 20 December 2018
- Published by Springer Nature in EJNMMI Research
- Vol. 8 (1) , 111
Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo
Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we developed a fast CLI method to detect tumour hypoxia with 18F-fluoromisonidazole (FMISO) for drug development purposes. Colon cancer model was induced in mice by subcutaneous injection of 1 × 106 CT-26 cells. FMISO was injected, and simultaneous PET-blood oxygen level dependent (BOLD)-MRI followed by CLI were performed along with immunohistochemistry staining with pimonidazole. There was a significant correlation between FMISO PET and CLI tumour uptakes, consistent with the BOLD-MRI mapping. Tumour-to-background ratio was significantly higher for CLI compared with PET and MRI. Immunohistochemistry confirmed tumour hypoxia. The imaging workflow with CLI was about eight times faster than the PET-MRI procedure. CLI is a fast and relevant tool to assess tumour hypoxia. This approach could be particularly interesting for hypoxia-targeting drug development.
- 20 December 2018
- Published by Springer Nature in EJNMMI Research
- Vol. 8 (1) , 111
Open AccessCherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo
Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we developed a fast CLI method to detect tumour hypoxia with 18F-fluoromisonidazole (FMISO) for drug development purposes. Colon cancer model was induced in mice by subcutaneous injection of 1 × 106 CT-26 cells. FMISO was injected, and simultaneous PET-blood oxygen level dependent (BOLD)-MRI followed by CLI were performed along with immunohistochemistry staining with pimonidazole. There was a significant correlation between FMISO PET and CLI tumour uptakes, consistent with the BOLD-MRI mapping. Tumour-to-background ratio was significantly higher for CLI compared with PET and MRI. Immunohistochemistry confirmed tumour hypoxia. The imaging workflow with CLI was about eight times faster than the PET-MRI procedure. CLI is a fast and relevant tool to assess tumour hypoxia. This approach could be particularly interesting for hypoxia-targeting drug development.